Company profile
LENZ Therapeutics, Inc.
NASDAQ: LENZ · Healthcare · Biotechnology
#554 of 1,422 Healthcare companies by revenue
EA Score
48DFH 57DQ 35GM —SS 48
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$21.0M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$82.1M
Employees
152
as of 2026-08-14
Market cap
$144.2M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$19.1M$19.1M2025
Net income-$82.1M-$82.1M2025
Operating income-$91.1M-$91.1M2025
Total assets$305.9M$305.9M2025
Liabilities$21.5M$21.5M2025
Equity$284.3M$284.3M2025
Revenue by segment
Filed disclosures · FY2025
By product
License92%
Product8%
By geography
Not disclosed.
The read
What is LENZ Therapeutics, Inc.’s revenue?
LENZ Therapeutics, Inc. booked $19.1M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -430.3% net margin.
Peers · Healthcare
Avem Health Partners, Inc.——cbdMD, Inc.49DPrecision Optics Corporation, Inc.61CViaDerma, Inc.——QT Imaging Holdings, Inc.40DNephros, Inc.75B+Neighbors
San Diego →Key facts
CEOEvert Schimmelpennink
SectorHealthcare
IndustryBiotechnology
HeadquartersSolana Beach, CA
ExchangeNASDAQ: LENZ
Employees152
IPO date2024-03-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.